What is KYMR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 9.35B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KYMR?

P/E (TTM) is n/a and 52-week range is $55.26 to $130.05 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KYMR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KYMR?

The company profile lists revenue (TTM) near $88M, net income (TTM) near $-25.10B, EPS (TTM) near $-3.24 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Kymera Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Watertown, Massachusetts, US, 82.3M shares outstanding, ISIN US5015751044 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Kymera Therapeutics Inc

$KYMR

Health Care · Biotechnology

IR Run Scenarios

$112.40

+2.84%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. The company is headquartered in Watertown, Massachusetts and currently employs 253 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The firm's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. The company is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. The company is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.

Employees

253

Website

www.kymeratx.com/

IPO

2020-08-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)